Titre
Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Hampel, B.
Auteure/Auteur
Kusejko, K.
Auteure/Auteur
Kouyos, R.D.
Auteure/Auteur
Böni, J.
Auteure/Auteur
Flepp, M.
Auteure/Auteur
Stöckle, M.
Auteure/Auteur
Conen, A.
Auteure/Auteur
Béguelin, C.
Auteure/Auteur
Künzler-Heule, P.
Auteure/Auteur
Nicca, D.
Auteure/Auteur
Schmidt, A.J.
Auteure/Auteur
Nguyen, H.
Auteure/Auteur
Delaloye, J.
Auteure/Auteur
Rougemont, M.
Auteure/Auteur
Bernasconi, E.
Auteure/Auteur
Rauch, A.
Auteure/Auteur
Günthard, H.F.
Auteure/Auteur
Braun, D.L.
Auteure/Auteur
Fehr, J.
Auteure/Auteur
Contributrices/contributeurs
Anagnostopoulos, A.
Battegay, M.
Bucher, H.C.
Calmy, A.
Cavassini, M.
Ciuffi, A.
Dollenmaier, G.
Egger, M.
Elzi, L.
Fellay, J.
Furrer, H.
Fux, C.A.
Haerry, D.
Hasse, B.
Hirsch, H.H.
Hoffmann, M.
Hösli, I.
Huber, M.
Kahlert, C.
Kaiser, L.
Keiser, O.
Klimkait, T.
Kovari, H.
Ledergerber, B.
Martinetti, G.
Martinez de Tejada, B.
Marzolini, C.
Metzner, K.J.
Müller, N.
Paioni, P.
Pantaleo, G.
Perreau, M.
Rudin, C.
Scherrer, A.U.
Schmid, P.
Speck, R.
Tarr, P.
Trkola, A.
Vernazza, P.
Wandeler, G.
Weber, R.
Yerly, S.
Groupes de travail
Swiss HIV Cohort Study group
Liens vers les personnes
Liens vers les unités
ISSN
1468-1293
Statut éditorial
Publié
Date de publication
2020-04
Volume
21
Numéro
4
Première page
228
Dernière page/numéro d’article
239
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Chemsex refers to the use of sex-enhancing drugs among men who have sex with men (MSM) in combination with specific sexual and social behaviours. Longitudinal data on this development and the associated health risks are scarce.
Data on all recreational drugs reported in the Swiss HIV Cohort Study (SHCS) from 2007 to 2017 were collected. Drug use was analysed longitudinally for all drug classes. In addition, potential associations between patient characteristics and the consumption of methamphetamine, γ-hydroxybutric acid/γ-butyrolactone (GHB/GBL), 3,4-methylenedioxymethamphetamine (MDMA/XTC), cocaine and amphetamine were analysed.
We analysed 166 167 follow-up entries for 12 527 SHCS participants, including 7101 free text field entries containing information about recreational drugs other than cannabis, cocaine and heroin. Overall, we observed a stable percentage (9.0%) of recreational drug use (excluding cannabis, amyl nitrite and prescription drugs). For MSM, however, there was an increase in overall drug use from 8.8% in 2007 to 13.8% in 2017, with particularly large increases for methamphetamine (from 0.2 to 2.4%; P < 0.001) and GHB/GBL (from 1.0 to 3.4%; P < 0.001). The use of each of the potentially sex-enhancing drugs methamphetamine, GHB/GBL, cocaine, XTC/MDMA and amphetamine was significantly associated with condomless sex with nonsteady partners, and higher prevalences of depression, syphilis and hepatitis C.
The significant increase in the use of chemsex drugs among MSM in the SHCS and the strong association with coinfections and depression highlights the need for harm reduction programmes tailored to MSM. According to our results, improving knowledge about recreational drugs is important for all health care professionals working with people living with HIV.
Data on all recreational drugs reported in the Swiss HIV Cohort Study (SHCS) from 2007 to 2017 were collected. Drug use was analysed longitudinally for all drug classes. In addition, potential associations between patient characteristics and the consumption of methamphetamine, γ-hydroxybutric acid/γ-butyrolactone (GHB/GBL), 3,4-methylenedioxymethamphetamine (MDMA/XTC), cocaine and amphetamine were analysed.
We analysed 166 167 follow-up entries for 12 527 SHCS participants, including 7101 free text field entries containing information about recreational drugs other than cannabis, cocaine and heroin. Overall, we observed a stable percentage (9.0%) of recreational drug use (excluding cannabis, amyl nitrite and prescription drugs). For MSM, however, there was an increase in overall drug use from 8.8% in 2007 to 13.8% in 2017, with particularly large increases for methamphetamine (from 0.2 to 2.4%; P < 0.001) and GHB/GBL (from 1.0 to 3.4%; P < 0.001). The use of each of the potentially sex-enhancing drugs methamphetamine, GHB/GBL, cocaine, XTC/MDMA and amphetamine was significantly associated with condomless sex with nonsteady partners, and higher prevalences of depression, syphilis and hepatitis C.
The significant increase in the use of chemsex drugs among MSM in the SHCS and the strong association with coinfections and depression highlights the need for harm reduction programmes tailored to MSM. According to our results, improving knowledge about recreational drugs is important for all health care professionals working with people living with HIV.
Sujets
PID Serval
serval:BIB_4A3CD01CDD1D
PMID
Open Access
Oui
Date de création
2019-12-19T10:24:46.549Z
Date de création dans IRIS
2025-05-20T15:40:16Z